Mican Technologies operates in the biotechnology sector, focusing on the production and supply of specialized blood cells through regenerative medicine technology. The company serves pharmaceutical companies, research institutions, and healthcare providers by offering homogeneous and highly accurate blood cells that improve the efficiency of infectious disease research and the evaluation of pharmaceuticals and functional materials. Mican Technologies' business model revolves around the sale of these specialized blood cells, SRIPs for safe infection evaluation, and evaluation kits for immediate cell-based testing. Revenue is generated through the direct sale of these products to its clients. The company has been recognized for its innovative contributions, winning the Tech Venture of the Year award in 2022 and participating in growth-oriented projects for small and medium enterprises.

Keywords: regenerative medicine, specialized blood cells, infectious disease research, pharmaceutical evaluation, homogeneous cells, SRIPs, cell-based testing, biotechnology, healthcare innovation, drug discovery.